<DOC>
	<DOCNO>NCT00051987</DOCNO>
	<brief_summary>The purpose study evaluate tumor patient colorectal carcinoma respond treatment VELCADE alone versus VELCADE give irinotecan , also see effect ( good bad ) cancer .</brief_summary>
	<brief_title>Phase 2b Study VELCADE Alone VELCADE Plus Irinotecan Patients With Relapsed Refractory Colorectal Carcinoma</brief_title>
	<detailed_description>In study , patient colorectal cancer longer respond standard medical treatment irinotecan irinotecan contain treatment randomize treatment VELCADE alone treatment VELCADE combination irinotecan .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Inclusion Criteria Patient histologically confirm inoperable locally advanced metastatic CRC . Patient measurable disease . Patient consider candidate immediate curative resection . Patient receive 2 prior treatment regimens metastatic disease , one must contain irinotecan . Patient relapse progressed receive irinotecancontaining regimen . Patient KPS 70 % great . Patient life expectancy great 3 month . Patient 18 year age old . Female patient postmenopausal , surgically sterilize , willing use acceptable method birth control ( ie , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male patient agree use acceptable method birth control duration study . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Patient , investigator 's opinion , willing able comply protocol requirement . Exclusion Criteria Patient great equal Grade 2 neuropathy define NCI Common Toxicity Criteria ( CTC ) : Grade 2 : Objective sensory loss paresthesia ( include tingle ) , interfere function , interfere activity daily live ( ADL ) . Grade 3 : Sensory loss paresthesia interfere ADL . Grade 4 : Permanent sensory loss interfere function . Patient previously receive treatment VELCADE . Patient malignancy except nonmelanoma skin cancer carcinoma cervix situ . Patient receive chemotherapy within 4 week prior enrollment . Patient receive radiation therapy within 4 week prior enrollment . Patient receive monoclonal antibody within 6 week prior enrollment . Patient major surgery within 4 week prior enrollment . Patient inadequate organ function Baseline ( ie , Day 1 Cycle 1 ) define follow laboratory value : Platelet count ≤ 100,000 x 109/L Hemoglobin ≤ 8.0 g/dL Absolute neutrophil count ( ANC ) ≤ 1.5 x 109/L Aspartate transaminase ( AST ) ≥ 3 time upper limit normal range ( ULN ) Alanine transaminase ( ALT ) ≥ 3 time ULN Total bilirubin ≥ 1.5 time ULN , unless clearly related disease Calculated measure creatinine clearance ≤ 60 mL/minute . Patient myocardial infarction within 6 month enrollment New York Hospital Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , electrocardiogram ( ECG ) abnormality Screening document investigator medically relevant . Patient symptomatic brain metastasis . Patient active systemic infection require treatment . Patient history inflammatory bowel disease . Patient history allergic reaction attributable compound contain boron mannitol . Patient previously require premature discontinuation irinotecan therapy drugrelated toxicity . Patient known human immunodeficiency virus ( HIV ) positive . Patients assess investigator risk HIV infection test accordance local regulation . Patient know hepatitis B surface antigenpositive know active hepatitis C infection . Patients assess investigator risk hepatitis B C infection test accordance local regulation . Patient poorly control hypertension , diabetes mellitus , another serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . Female patient pregnant breastfeeding . Confirmation patient pregnant must establish negative serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test result obtain Screening period . Pregnancy test require postmenopausal surgically sterilize woman . Patient currently enrol another clinical research study receive investigational agent reason within 4 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>